ID   CRMM-1
AC   CVCL_M593
SY   CRMM1; Conjunctival Recurrent Malignant Melanoma-1
DR   cancercelllines; CVCL_M593
DR   Cosmic; 2639616
DR   Wikidata; Q54814503
RX   PubMed=15993408;
RX   PubMed=22275346;
RX   PubMed=25722211;
RX   PubMed=28903377;
RX   PubMed=32545782;
CC   Characteristics: Can form 3D spheroids (PubMed=32545782).
CC   Doubling time: ~60 hours (Note=At passages 20 to 40) (PubMed=15993408).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=25722211).
CC   Derived from site: In situ; Eye, bulbar conjunctiva; UBERON=UBERON_0010306.
ST   Source(s): PubMed=25722211
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D13S317: 12
ST   D16S539: 11
ST   D18S51: 12,17
ST   D19S433: 13,14
ST   D21S11: 29,32.2
ST   D2S1338: 17,20
ST   D3S1358: 15,18
ST   D5S818: 12,13
ST   D7S820: 8,11
ST   D8S1179: 14
ST   FGA: 21,23
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 15
DI   NCIt; C4550; Conjunctival melanoma
DI   ORDO; Orphanet_617910; Conjunctival malignant melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 19-12-24; Version: 14
//
RX   PubMed=15993408; DOI=10.1016/j.exer.2005.04.018;
RA   Nareyeck G., Wuestemeyer H., von der Haar D., Anastassiou G.;
RT   "Establishment of two cell lines derived from conjunctival
RT   melanomas.";
RL   Exp. Eye Res. 81:361-362(2005).
//
RX   PubMed=22275346; DOI=10.1136/bjophthalmol-2011-300686;
RA   Westekemper H., Freistuehler M., Anastassiou G., Nareyeck G.,
RA   Bornfeld N., Steuhl K.-P., Scheulen M.E., Hilger R.A.;
RT   "Chemosensitivity of conjunctival melanoma cell lines to single
RT   chemotherapeutic agents and combinations.";
RL   Br. J. Ophthalmol. 96:591-596(2012).
//
RX   PubMed=25722211; DOI=10.1167/iovs.14-15239;
RA   de Waard N.E., Cao J.-F., McGuire S.P., Kolovou P.E., Jordanova E.S.,
RA   Ksander B.R., Jager M.J.;
RT   "A murine model for metastatic conjunctival melanoma.";
RL   Invest. Ophthalmol. Vis. Sci. 56:2325-2333(2015).
//
RX   PubMed=28903377; DOI=10.18632/oncotarget.18039; PMCID=PMC5589616;
RA   Cao J.-F., Brouwer N.J., Richards K.E., Marinkovic M., van Duinen S.,
RA   Hurkmans D., Verdegaal E.M.E., Jordanova E.S., Jager M.J.;
RT   "PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in
RT   conjunctival melanoma.";
RL   Oncotarget 8:54722-54734(2017).
//
RX   PubMed=32545782; DOI=10.3390/biomedicines8060158; PMCID=PMC7344416;
RA   Fiorentzis M., Katopodis P., Kalirai H., Seitz B., Viestenz A.,
RA   Coupland S.E.;
RT   "Image analysis of 3D conjunctival melanoma cell cultures following
RT   electrochemotherapy.";
RL   Biomedicines 8:158.1-158.13(2020).
//